Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tick-borne encephalitis vaccine, inactivated
- Development stage
- Approved
- Lead developer
- Changchun Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tick-borne encephalitis vaccine, inactivated is a monovalent viral vaccine designed to provide active immunity against the tick-borne encephalitis virus (TBEV). Developed by the Changchun Institute of Biological Products (CCIBP), this specific inactivated formulation is typically produced by propagating the virus (such as the Senzhang strain) in cell culture, followed by formaldehyde inactivation and purification. The vaccine is administered via intramuscular injection and includes an aluminum-based adjuvant to enhance the immune response. It is primarily indicated for individuals living in or traveling to endemic regions where the virus is transmitted through the bite of infected Ixodes ticks. Clinical trials, such as CTR20221152, have focused on evaluating the immunogenicity and safety of the vaccine in various populations, including those over 8 years of age.
- Brand names
- SenmianFSME-IMMUNEncepurTicovacTBE-MoskvaEnceVir
- Other names
- Forest encephalitis vaccine, inactivated森林脑炎灭活疫苗
02
Targets
BCR (B-cell receptor)E (Tick-borne encephalitis virus envelope protein)T-cell receptor recognizing tick-borne encephalitis virus-derived peptide–MHC complexes
Beyond the preview
Go deeper on tick-borne encephalitis vaccine, inactivated.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tick-borne encephalitis vaccine, inactivated.